| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
iSpecimen Inc. Common Stock$1.89
+0.06 (+3.28%)
F 1Pipeline Score Biotech · Clinical
Market Cap
3.80 M
EPS
-2.20
P/E Ratio
-0.06 $
Value Trade
386.18 K
SEC Financials
Q1 2026Dilution Risk
Revenue
156.01 K
Operating CF
-3.36 M
Total Assets
6.61 M
Total Liabilities
5.80 M
Equity
814.04 K
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
2.82 M
Monthly Burn
1.12 M
Runway
0.2 mo
Burn Trend
SEC Filing
May 18, 2026
Overview
Volume
35.79 K
52 Week Range
0.13 - 3.18
% held by Insiders
0.07 %
% held by Institutions
1.41 %
Enterprise Value
-2.81 M
Total Shares
1.44 M
Short %
12.84 %
Float Shares
1.44 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for iSpecimen Inc. Common Stock
42Total events
0Upcoming
0Tier-1 (high impact)
2021 – 2026Coverage
Event history 2
TBD
▼Equity OfferingCorporate
Subscribe to view catalyst details
TBD
▼Reverse Stock SplitCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F1
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 3%
Micro Cap (rank 897 of 924)
Percentile RankiSpecimen Inc. Common Stock has significant pipeline risk (1/100), but cash runway is a concern.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ISPC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ISPC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-ISPC
May 9, 2026iSpecimen Inc. Announces Pricing of Approximately $2.5 Million Private Placement
iSpecimen Inc. has announced a private placement offering priced at approximately $2.5 million, set to close around May 11, 2026. The company will issue 488,281 shares at $5.12 each, with options for pre-funded warrants. Proceeds will be used for working capital, including marketing expenses. The offering is subject to stockholder approval for additional share issuance.
Read more →-ISPC
Apr 24, 2026▼ -19.6%on this news· ran to -34% by day 3
iSpecimen Announces 1-for-40 Reverse Stock Split
iSpecimen announced a 1-for-40 reverse stock split of its common stock, effective April 27, 2026, to raise its trading price and attract institutional investors. This decision follows the approval of stockholders and aims to comply with Nasdaq's minimum bid price requirement. The company will reduce its total outstanding shares from approximately 52.6 million to around 1.3 million. Adjustments will also be made to stock options and incentive plans in line with the split.
Read more →-ISPC
Apr 9, 2026▼ -10.3%on this news· ran to -25% by day 3
iSpecimen achieves 85% Reduction in Human Biospecimen Shipping Time Woburn, MA
iSpecimen has launched a new shipping model that reduces human biospecimen transit times by 70-85%, cutting delivery times down to as little as 1-2 days. This model eliminates the need for centralized hub processing and allows for direct shipments from supplier sites to customers globally. Enhanced partnerships in Europe and Eastern Europe facilitate access to rare biospecimens, while positive customer feedback emphasizes improved reliability and service quality following the changes.
Read more →-ISPC
Feb 6, 2026iSpecimen Achieves Rapid Procurement Milestone for Influenza Research
iSpecimen has successfully reached a rapid procurement milestone aimed at advancing influenza research. This achievement is expected to significantly enhance the company's capabilities in providing biological samples for research purposes. The milestone underscores iSpecimen's commitment to supporting public health initiatives through improved research resources.
Read more →-ISPC
Feb 6, 2026iSpecimen Announces Milestone 2: System Integration and Marketplace Activation Complete
iSpecimen has announced the successful completion of Milestone 2, which includes the integration of their system and activation of their marketplace. This achievement is expected to enhance their operational capabilities and improve access to biospecimens. The company is optimistic about the future prospects following this milestone.
Read more →-ISPC
Sep 4, 2025iSpecimen Approached by Crypto Currency Companies for $200 Million Treasury Discussions Woburn, MA
iSpecimen Inc. has announced its strategic initiative to integrate digital assets into its business model, aiming to establish a corporate treasury reserve of up to $200 million using the Solana blockchain. Following this initiative, iSpecimen has received interest from several cryptocurrency companies concerning tokenized real-world assets. The CEO indicated a focus on diversifying the company's balance sheet while implementing treasury management strategies. However, the venture is subject to market volatility and regulatory uncertainties that could impact the company's growth prospects.
Read more →-ISPC
Aug 21, 2025▼ -29.8%on this news
iSpecimen Announces Completion of Milestone 1 in Digital Transformation Journey with Salestack Platform Woburn, MA
iSpecimen Inc. has announced the successful completion of Milestone 1 in its digital transformation journey, powered by Salestack Solutions. This milestone involves enhancing the iSpecimen Marketplace's infrastructure, enabling improved operational efficiency and scalability. The completion is seen as a significant step towards creating a more efficient and secure marketplace, with future phases aimed at further integration and automation. CEO Robert Lim expressed optimism about unlocking greater efficiencies and enhancing marketplace capabilities as the company progresses.
Read more →-ISPC
Aug 7, 2025▲ +6.5%on this news· ran to -32% by day 3
iSpecimen to Establish $200M Corporate Treasury Built Around Solana Cryptocurrency with BlockArrow Woburn, MA
iSpecimen has announced plans to build a corporate treasury of up to $200 million focusing on the Solana cryptocurrency, aiming to support long-term innovation and technology advancement. The initiative will involve partnerships with WestPark Capital and BlockArrow for advisory and management services, emphasizing security and compliance in handling digital assets. iSpecimen views this as a step towards financial and operational innovation, positioning itself as a leader in integrating blockchain technology within life sciences. The company aims to diversify its digital treasury across high-performing crypto assets with an initial focus on Solana.
Read more →-ISPC
Jul 31, 2025iSpecimen Inc. Announces Pricing of Approximately $1.75 Million Private Placement Priced At-the-Market
iSpecimen Inc. announced a private placement agreement with accredited investors, expected to yield approximately $1.75 million. The company will use the proceeds primarily for marketing and general corporate purposes. The offering is set to close around August 1, 2025, pending customary closing conditions. This funding aims to enhance iSpecimen's operations as it supports the research needs of scientists across various organizations.
Read more →-ISPC
Jul 24, 2025iSpecimen Inc. Announces Pricing of $4 Million Underwritten Offering
iSpecimen Inc. has announced the pricing of a public offering for 5,714,283 shares of its common stock at $0.70 per share, aiming to raise approximately $4 million. The offering is set to close on July 25, 2025, pending customary closing conditions. The company plans to use the proceeds for marketing, initial payments to Sales Stack Solutions, and for working capital. The offering is being conducted on a firm commitment basis by WestPark Capital, Inc.
Read more →-ISPC
Jan 16, 2025▲ +8%on this news
iSpecimen Secures Suppliers for COVID-style hMPV Outbreak
iSpecimen Inc. has announced the acquisition of suppliers to handle a potential outbreak of human metapneumovirus (hMPV), which has been impacting hospitals in China. As hMPV spreads through respiratory droplets, it raises fears of a situation comparable to the COVID-19 pandemic. Currently, there is no vaccine for hMPV, emphasizing the vital need for high-quality biospecimens for research and vaccine development. iSpecimen aims to address this increasing demand through its global partnerships and advanced online marketplace for human biospecimens.
Read more →-ISPC
Dec 20, 2024iSpecimen will serve as a Preferred Provider of Cancer Biospecimens Woburn, MA
iSpecimen Inc. has announced strategic initiatives for 2025, positioning itself as a preferred provider of cancer biospecimens. The company plans to enhance access through new partnerships with U.S.-based cancer centers and establish a referral program with an international genomic sequencing partner. This will improve procurement efficiency for researchers and support advancements in cancer research. iSpecimen's data-driven strategies aim to streamline the specimen procurement process and expand its offerings, particularly in cancer-related biofluids.
Read more →-ISPC
Dec 13, 2024▼ -15.4%on this news
iSpecimen Reports Positive Results on Next Day Quote Program for Researchers and Providers
iSpecimen Inc. reported positive results from its Next Day Quote Program, designed to expedite the biospecimen pricing process for researchers. Launched in 2023, the program has demonstrated significant adoption, with 30% of sales opportunities and 48% of total quotes in November 2024 attributed to it. Senior Vice President Leslie Hoyt highlighted that swift quoting greatly increases the likelihood of purchase orders, underlining the program's effectiveness in meeting customer needs.
Read more →-ISPC
Dec 12, 2024iSpecimen Appoints Robert Lim as CEO and Director
iSpecimen Inc. has appointed Robert Lim as its new CEO and director. Lim has a background as the co-founder of a law firm and extensive experience in legal and marketing fields. His leadership is expected to foster innovative approaches for the company, enhancing operations and profitability in the biospecimen marketplace. iSpecimen connects researchers with healthcare providers to facilitate medical discovery through its online platform.
Read more →-ISPC
Oct 29, 2024iSpecimen Inc. Announces Pricing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants
iSpecimen Inc. has announced the pricing of a $5 million public offering of its common stock and pre-funded warrants, priced at $3.00 per share. The company plans to use the proceeds for several strategic purposes, including debt repayment, potential acquisitions, and enhancing marketing efforts. The offering is expected to close on October 31, 2024, pending customary closing conditions. The related securities are being offered under a registration statement recently declared effective by the SEC.
Read more →-ISPC
Sep 11, 2024iSpecimen Announces 1-for-20 Reverse Stock Split
iSpecimen Inc. announced a 1-for-20 reverse stock split of its common shares, effective September 13, 2024. The decision follows the approval from stockholders and aims to increase share price to attract institutional investors and meet Nasdaq listing requirements. The adjusted shares will trade under the same ticker symbol, ISPC. Broadridge Corporate Issuer Solutions will serve as the exchange agent for this stock split.
Read more →-ISPC
Aug 6, 2024iSpecimen Reports Second Quarter 2024 Results Revenue increased 76% year-over-year to approximately $2.86 million Brielan Smiechowski Named SVP of Sales and Business Development
iSpecimen Inc. reported a substantial revenue increase of 76% year-over-year, reaching approximately $2.86 million for the second quarter of 2024, driven by higher specimen counts and an increase in average selling prices. The company also welcomed Brielan Smiechowski as the new Senior Vice President of Sales and Business Development. While costs have decreased significantly, iSpecimen still faced a net loss of approximately $2.11 million in the quarter. Overall, the company is focusing on improving operational efficiency and enhancing shareholder value.
Read more →-ISPC
May 7, 2024iSpecimen Reports First Quarter 2024 Results
iSpecimen Inc. reported its first-quarter results for 2024, indicating a drop in revenue and specimen count, while improving its Next Day Quotes program. Revenue decreased to approximately $2.29 million, primarily due to a decline in specimen transactions. However, the company noted a significant increase in the average price per specimen and a high conversion rate of quotes to purchase orders, suggesting positive trends in operational initiatives despite financial challenges. The net loss widened to approximately $2.90 million compared to the previous year's loss.
Read more →-ISPC
Mar 14, 2024iSpecimen Reports Full Year 2023 Results LEXINGTON, Mass., March 14 2024 - iSpecimen Inc . (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for m
iSpecimen Inc. reported its financial results for the year ending December 31, 2023, revealing a revenue decrease to approximately $9.93 million. The company emphasized its efforts to achieve profitability through operational efficiencies and growth in topline revenue, particularly with the new Next Day Quotes initiative, which saw significant success. Despite these efforts, iSpecimen incurred a larger net loss of approximately $11.10 million due to a reduction in specimen count. The company has also seen improvements in managing operating expenses, demonstrating a focus on financial health moving forward.
Read more →-ISPC
Nov 2, 2023iSpecimen Reports Third Quarter 2023 Financial and Operating Results Sequential Quarterly Revenue Growth of 75% Driven by Enhanced Operational Efficiencies of iSpecimen Marketplace and Rollout of New Business Initiatives
iSpecimen Inc. reported a noteworthy 75% growth in revenue for the third quarter of 2023, attributed to operational efficiencies and new business initiatives. The introduction of the Next-Day Quote Program has streamlined the procurement process, leading to increased order conversions. However, the company still recorded a net loss of $2.1 million despite improved performance compared to the previous year. Overall, while revenue has slightly decreased for the nine-month period, iSpecimen's efforts in enhancing their Cancer Sequencing Procurement Program indicate potential future growth.
Read more →-ISPC
Oct 23, 2023iSpecimen Preannounces Third Quarter 2023 Revenue Increase of 60-70% Sequentially Management to Host Third Quarter 2023 Conference Call on Thursday
iSpecimen Inc. has announced a preliminary financial forecast indicating a revenue increase of 60-70% for the third quarter of 2023, expecting it to be between $2.6 to $2.8 million. The company attributes this growth primarily to its new next-day quote program, which has enhanced the efficiency of biospecimen transactions. In light of these developments, management expresses optimism about future revenue growth and operational improvements. A conference call is scheduled for November 2, 2023, to discuss the financial results in further detail.
Read more →-ISPC
Sep 6, 2023iSpecimen Announces Organizational Changes to Enhance Operational Efficiencies and Drive Profitability Company to Focus on Core Revenue Drivers, New Revenue Growth Opportunities from Recently Launched Sequencing Procurem
iSpecimen Inc. has announced a restructuring plan aimed at improving operational efficiency and profitability, which includes a 20% reduction in workforce. The company has also launched a new virtual cancer sequencing procurement program to facilitate easier access to tumor tissues for researchers. These initiatives are expected to lower monthly expenses significantly while responding to market demand for valuable biospecimens. iSpecimen remains committed to achieving cash flow neutrality and profitability in the near future.
Read more →-ISPC
Aug 2, 2023iSpecimen Reports Second Quarter 2023 Financial and Operating Results
iSpecimen Inc. reported its financial results for the second quarter of 2023, showing a revenue decrease of 31% year-over-year due to a decline in order requests amid an industry-wide funding slowdown. Despite the downturn, the company introduced several new initiatives aimed at enhancing revenue and technology integration. The backlog showed improvement, raising hopes for recovery in the upcoming quarter. However, the company also posted a higher net loss compared to the previous year, underscoring ongoing challenges in its business model.
Read more →-ISPC
May 4, 2023iSpecimen Reports First Quarter 2023 Results - Quarterly Revenue Increased 17% Year-Over-Year - LEXINGTON, MA
iSpecimen Inc. reported financial results for the first quarter of 2023, showing a 17% increase in revenue to approximately $3.0 million compared to the previous year. The increase was driven by a 75% rise in specimen count, though average selling prices per specimen fell by 30%. Despite these gains, the company reported a consistent net loss of $2.4 million, and cash reserves decreased significantly. The leadership remains optimistic about future revenue opportunities stemming from strategic investments and operational improvements.
Read more →-ISPC
Mar 14, 2023iSpecimen Reports Full Year 2022 Results - Reported Record Quarterly Revenue of $3.2 Million, Up 28% Year-Over-Year - LEXINGTON, MA
iSpecimen Inc. reported a record revenue of $3.2 million for Q4 2022, achieving a 28% increase year-over-year. The company has made strategic improvements and appointed new leadership to enhance operations and revenue generation. However, despite the quarterly growth, the full year showed a revenue decline to approximately $10.4 million compared to 2021. The net loss also increased, indicating ongoing financial challenges, as cash reserves significantly decreased from the previous year.
Read more →-ISPC
Jan 10, 2023iSpecimen Names Tracy Curley as Chief Executive Officer -- Previously Appointed Interim CEO in September 2022
iSpecimen Inc. has appointed Tracy Curley as CEO, following her role as Interim CEO since September 2022. Curley has demonstrated goal-oriented leadership and contributed to significant operational and financial achievements, including record revenue in the fourth quarter of 2022. The company plans to begin a search for a new CFO following this leadership transition, signaling strategic planning for future growth.
Read more →-ISPC
Nov 8, 2022iSpecimen Reports Third Quarter 2022 Financial and Operating Results - Reported Revenue of $2.6 Million, Comprised Of A Record 88% Non-COVID Revenue - LEXINGTON, MA
iSpecimen Reports Third Quarter 2022 Financial and Operating Results - Reported Revenue of $2.6 Million, Comprised Of A Record 88% Non-COVID Revenue - LEXINGTON, MA, November 8, 2022 - iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online global marketplac
Read more →-ISPC
Sep 22, 2022iSpecimen Names Chief Financial Officer, Tracy Curley, Interim CEO -- Current President and CEO, Christopher Ianelli, to Leave Company
Names Chief Financial Officer, Tracy Curley, Interim CEO President and CEO, Christopher Ianelli, to Leave Company September 22, 2022 - iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists in need of biospecimens fo
Read more →-ISPC
Aug 4, 2022iSpecimen Reports Second Quarter 2022 Financial and Operating Results - Enhanced iSpecimen Marketplace Platform with Data Integration Capabilities to Simplify the Ingestion and Maintenance of Biospecimen Inventories for
Reports Second Quarter 2022 Financial and Operating Results - Enhanced iSpecimen Marketplace Platform with Data Integration Capabilities to Simplify the Ingestion and Maintenance of Biospecimen Inventories for Providers - MA, August 4, 2022 - iSpecimen Inc. (Nasdaq: ISPC) ("iS
Read more →-ISPC
May 10, 2022iSpecimen Reports First Quarter 2022 Financial and Operating Results - Recently Launched Enhanced iSpecimen Marketplace Platform to Help Scientists More Efficiently Search for Biospecimens - LEXINGTON, MA
iSpecimen Reports First Quarter 2022 Financial and Operating Results - Recently Launched Enhanced iSpecimen Marketplace Platform to Help Scientists More Efficiently Search for Biospecimens - LEXINGTON, MA, May 10, 2022 - iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Com
Read more →-ISPC
Feb 17, 2022iSpecimen Reports Full Year 2021 Financial Results - Record FY 2021 Revenue of $11.1 Million, Surpassing FY 2020 Revenue of $8.2 Million by 36% - LEXINGTON, MA
iSpecimen Reports Full Year 2021 Financial Results - Record FY 2021 Revenue of $11.1 Million, Surpassing FY 2020 Revenue of $8.2 Million by 36% - LEXINGTON, MA, February 17, 2021 - iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online marketplace for human b
Read more →-ISPC
Dec 1, 2021iSpecimen Inc. Announces Closing of Approximately $21 Million Private Placement
Inc. Announces Closing of Approximately $21 Million Private Placement Dec. 1, 2021 /PRNewswire/ -- iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens, today announced that it has closed its previously announced private pla
Read more →-ISPC
Nov 28, 2021iSpecimen Inc. Announces $21 Million Private Placement
iSpecimen Inc. Announces $21 Million LEXINGTON, Mass., Nov. 28, 2021 /PRNewswire/ -- iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens, today announced that it has entered into a definitive securities purchase agreement
Read more →-ISPC
Nov 4, 2021CONNECT. INNOVATE. November 2021 Investor Presentation TRANSFORMING BIOSPECIMEN PROCUREMENT An online marketplace for human biospecimens This presentation may contain forward - looking statements within the meaning of Se
CONNECT. INNOVATE. November 2021 Investor Presentation TRANSFORMING BIOSPECIMEN PROCUREMENT An online marketplace for human biospecimens This presentation may contain forward - looking statements within the meaning of Section 27 A of the Securities Act of 1933 , as amended, and
Read more →-ISPC
Aug 10, 2021iSpecimen Reports Second Quarter 2021 Financial Results -Delivered Revenue Growth of 93% Year-Over-Year- -Successfully Completed IPO Raising Total Gross Proceeds of $20.7 Million- LEXINGTON, MA
iSpecimen Reports Second Quarter 2021 Financial -Delivered Revenue Growth of 93% Year-Over-Year- -Successfully Completed IPO Raising Total Gross Proceeds of $20.7 Million- August 10, 2021 - iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online marketplace f
Read more →-ISPC
Jul 1, 2021iSpecimen Announces Closing of Over-Allotment Option in Connection with its Initial Public Offering LEXINGTON, MA
Announces Closing of Over-Allotment Option Connection with its Initial Public Offering MA, July 1, 2021 /PRNewswire/ - iSpecimen Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens, today announced the closing of the issuance of an
Read more →-ISPC
Jun 16, 2021iSpecimen Announces Pricing of Initial Public Offering
Pricing of Initial Public Offering Mass., June 16, 2021 /PRNewswire/ -- iSpecimen Inc. ("iSpecimen" or the "Company"), an online marketplace for human biospecimens, today announced the pricing of its initial public offering of 2,250,000 shares of its common stock at a price of
Read more →Competitive Position
How ISPC ranks across every disease it competes inCompetitive Position is a premium feature
See how ISPC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial